| Prev Close | 147.76 |
| Day Low/High | 143.97 / 150.82 |
| 52 Wk Low/High | 106.11 / 150.19 |
| Avg Volume | 1.39M |
McKesson Corp. (MCK)
144.85
NYSE : Distribution Services
| Exchange | NYSE |
| Shares Outstanding | 184.90M |
| Market Cap | 27.32B |
| EPS | 0.20 |
| P/E Ratio | 47.21 |
| Div & Yield | 1.64 (1.06%) |
Trader's Daily Notebook: Uncertainty Leads to Assets' Repricing
I continue to believe downside risks far outweigh the risks of a near-term rally.
Cramer: Investors Look at Merck, Wondering Why They Did Not Buy Qualcomm
In a "take no pain, take no prisoners" market, health care stocks languish.
Stocks Under $10 Portfolio: Tax-Loss Selling Weighs on Indices
We used this week's declines to add to our positions in Teligent, Builders FirstSource and Sonus Networks.
McKesson Shares Plunge on Drug Price Cuts
Shares of the drug distributor were falling sharply Friday.
Stressed Out: Valeant Shareholders Flee on McKesson Warning
The drugmaker's shares were hammered Friday on news that the industry is slashing prices.
Trending Tickers: HSY, RCL, MCK, VRX
Hershey shares got an early Halloween treat Friday after earnings topped analyst forecasts.
Jim Cramer Explains Why Health Care Stocks are Getting Slammed on Wall Street Today
McKesson's disappointing earnings report ignited a selloff in health care stocks, and Jim Cramer says investors are questioning the sector's future.
Jim Cramer: Healthcare Stocks in Crosshairs
The pricing structure of the healthcare and drug distribution industry has been wrecked and Wall Street is taking down those stocks as a result, says Jim Cramer.
Bullish & Bearish Reversals for the Week
Energy and consumer defensive names dominate on the bearish side.
McKesson's Correction Is not Just a Third-Quarter Issue
Keep your powder dry and see if MCK tries to makes a double bottom.
Ignore the Political Debate and Buy These 4 Cheap Pharma Stocks
McKesson is down 10 percent year-to-date due to the heated political debate over drug pricing but the stock is too cheap to ignore.
Cramer: The Answer to This Market: Part 1
The leadership is quite stark.
'Timeliness' Isn't Always on Your Side
In the case of McKesson, Value Line system doesn't do investors any favors.
Cramer: There Isn't Very Much to Buy, Despite the Dip
There are issues everywhere, in almost every group.
When Covered Call Writing Makes Sense
The strategy doesn't deserve a lot of the criticism it gets.
Not Messin' With McKesson (Long)
Charts push for the short position.
It Looks Like McKesson Is Forming a Bottom
But try to have your buy orders below the market, in the $165 area.
9 Health Names to Like Amid the Rhetoric
Candidates have decried rising drug and medical prices, but there are reasons to like these stocks.
McCormick Turns Up the Heat on Premier Foods
Undeterred by previous snubs, spicemaker McCormick makes a revised approach to Britain's Premier Foods, raising the proposed enterprise value to $2.16 billion.
Bearish Signals Are Rising
The market went too far, too fast.
Jim Cramer Says Procter & Gamble, Kimberly Clark Are 'Screaming Buys’
TheStreet’s Jim Cramer says he thinks Visa will go up substantially, and that consumer products companies Kimberly Clark and Procter & Gamble are ‘screaming buys.'
U.S. Futures Take Negative Turn Following Conclusion of Fed Meeting
U.S. futures are falling premarket.
McKesson to Pay $1.2 Billion for Pair of Oncology Businesses
McKesson revealed Thursday a pair of acquisitions that will grow its oncology business.
McKesson Multiple Sits at Swell Entry Point
Why be afraid to own a world leader in health care at a multiyear best valuation?
McKesson Could Use a Shot in the Arm; Chart Shows Potential 25% Downside
After reading the chart action, we see $120 as the next stopping point.
This Is What an Oversold Bounce Looks Like
But wait to see what the analysts do.
